Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel. Ysios participated.

09/06/2022 Press release MINERALYS THERAPEUTICS CLOSES $118 MILLION OVERSUBSCRIBED SERIES B FINANCING TO ADVANCE THE DEVELOPMENT OF NOVEL. YSIOS CAPITAL PARTICIPATED. Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel. Ysios participated. MLS-101 is a Highly Selective Aldosterone Synthase Inhibitor Designed to Address Abnormally Elevated Aldosterone, an Underlying Cause…

Ysios Capital participa en la ronda de financiación de $118 millones en Mineralys Therapeutics

09/06/2022 Nota de prensa YSIOS CAPITAL PARTICIPA EN LA RONDA DE FINANCIACIÓN DE $118 MILLONES EN MINERALYS THERAPEUTICS. La entidad de capital riesgo (venture capital) Ysios Capital participa en la ronda de financiación de 118 millones de dólares en Mineralys Therapeutics − Mineralys Therapeutics Inc. (Pensilvania, Estados Unidos), es una compañía biotecnológica en fase clínica…